Download MendeleyNovel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays.
Jones, L.H., Allan, G., Barba, O., Burt, C., Corbau, R., Dupont, T., Knochel, T., Irving, S., Middleton, D.S., Mowbray, C.E., Perros, M., Ringrose, H., Swain, N.A., Webster, R., Westby, M., Phillips, C.(2009) J Med Chem 52: 1219
- PubMed: 19175319
- DOI: https://doi.org/10.1021/jm801322h
- Primary Citation of Related Structures:
2JLE - PubMed Abstract:
A major problem associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV is their lack of resilience to mutations in the reverse transcriptase (RT) enzyme. Using structural overlays of the known inhibitors efavirenz and capravirine complexed in RT as a starting point, and structure-based drug design techniques, we have created a novel series of indazole NNRTIs that possess excellent metabolic stability and mutant resilience.
Organizational Affiliation:
Discovery Chemistry, Sandwich Laboratories, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom. Lyn.Jones@pfizer.com
